Eco Animal Health adds £10 million sheep vaccine opportunity through Vaxinano deal

Eco Animal Health Group PLC has signed a perpetual exclusive licence agreement with French biotechnology company Vaxinano for a sheep vaccine candidate targeting toxoplasmosis.

The deal gives Eco Animal Health the right to complete development and commercialise the late-stage candidate across important sheep-rearing markets worldwide. The technology is patent-protected, although the announcement does not disclose when that protection expires.

For investors, the attraction is straightforward. Eco is adding a potentially meaningful product to its preventative medicines pipeline without increasing its planned research and development spending. Management estimates peak annual sales of approximately £10 million in the UK and Europe alone.

However, this remains a development-stage opportunity rather than commercial revenue in hand. The route to approval, launch timing and expected development costs were not disclosed.

The Vaxinano agreement at a glance

Detail	Disclosure
Vaccine target	Toxoplasmosis in sheep
Development stage	Late-stage
Licence	Perpetual and exclusive
Geographic coverage	Important sheep-rearing markets worldwide
Upfront fee	Described as modest, amount not disclosed
Development milestone	Payable in future, amount not disclosed
Royalties	Based on future product sales, rate not disclosed
Estimated peak annual sales	Approximately £10 million in the UK and Europe alone
Additional R&D expenditure	None envisaged
Commercial launch timetable	Not disclosed

The full terms can be found in the original company announcement.

What Eco Animal Health is licensing

Toxoplasmosis is a recognised disease in sheep caused by the parasite Toxoplasma gondii. It can lead to abortion, stillbirth and weak lambs, creating reproductive losses for livestock producers.

Eco's licence covers a vaccine candidate intended to prevent those reproductive failures. A prophylactic vaccine is one designed to prevent disease rather than treat it after infection.

Vaxinano develops needle-free vaccines using its STELLAR-NP platform. According to the announcement, the platform carries antigen across the nasal mucosa using biosourced nanoparticles, without an adjuvant or refrigeration. An antigen is the substance used to trigger an immune response, while an adjuvant is an ingredient sometimes added to strengthen that response.

The candidate's precise administration method, clinical data and remaining regulatory requirements were not disclosed in this announcement.

Why this could matter for Eco Animal Health

The agreement fits Eco's effort to build a broader vaccine business alongside its established veterinary medicines operation.

Its lead product, Aivlosin, is an antibiotic used to treat respiratory and intestinal diseases in pigs and poultry. It is distributed in more than 70 markets through the company's existing commercial platform.

Vaccines offer Eco a route into preventative animal health products and alternatives to antibiotics. That strategic shift has already moved beyond research: ECOVAXXIN MS, a poultry vaccine targeting Mycoplasma synoviae, was commercially launched in the EU in July 2026.

That first launch provided important context in the company's recent results and vaccine growth update. The Vaxinano deal now adds another candidate, this time focused on sheep rather than poultry.

It also gives Eco a way to supplement its proprietary research pipeline through in-licensing. In-licensing means acquiring commercial and development rights to technology created by another organisation, rather than developing the asset entirely in-house.

This can be an efficient way to expand a pipeline, particularly when the candidate is already described as late-stage. Eco believes its existing commercial and distribution infrastructure can support a faster and less risky route to market than starting from an early research programme.

That is management's assessment, rather than a guarantee. Regulatory and development risk still remain until the product reaches commercial launch.

The financial structure looks controlled

Eco will pay Vaxinano a modest upfront licence fee, followed by a future development milestone payment and royalties linked to commercial sales.

The actual figures and royalty rate were not disclosed. That limits investors' ability to calculate the product's potential profit contribution from the £10 million peak sales estimate.

Even so, the funding comments are encouraging. Eco says:

• the investment will be funded from operating cash flow;
• no increase in planned R&D expenditure is envisaged; and
• the upfront fee is already accommodated within the current financial year's R&D budget.

In other words, the company is not announcing a surprise increase in research spending to support the deal. It is fitting the programme into its existing investment plans.

That reduces the immediate financial risk, although the lack of detailed payment terms means the total potential commitment is not yet clear.

The £10 million sales estimate needs context

Management estimates that the vaccine could generate peak annual sales of approximately £10 million in the UK and Europe alone.

That would be meaningful for a new product, particularly because the licence covers other important sheep-rearing markets worldwide. No sales estimate was provided for territories outside the UK and Europe.

Investors should nevertheless treat peak sales as a long-term management estimate, not a near-term revenue forecast. The announcement does not disclose:

• when regulatory submissions will take place;
• when approval might be secured;
• when commercial sales could begin;
• how quickly the product could reach peak sales;
• expected pricing or market share; or
• the margin after royalties and other costs.

Those omissions do not undermine the strategic logic, but they make it too early to assign the full estimated revenue opportunity to Eco's current earnings.

Positives and risks for investors

Potential positives

The candidate is already at a late stage of development, which may offer a shorter route to market than an early research asset. Eco also has an established international commercial platform and recently launched its first proprietary vaccine in the EU.

The deal strengthens the preventative medicines pipeline without requiring additional planned R&D expenditure. Meanwhile, the estimated £10 million of peak annual sales in the UK and Europe suggests the product could make a meaningful contribution if development and commercialisation succeed.

The worldwide licence may also provide scope beyond the disclosed UK and European estimate.

Points to watch

There is no disclosed approval or launch timetable, and a late-stage candidate can still encounter development or regulatory setbacks.

The financial terms are only described in broad language. Investors do not know the upfront payment, milestone amount, royalty rate or total remaining development cost.

The £10 million figure is an estimate of peak annual sales, not a forecast for the next financial year. Commercial adoption, competition, pricing and regulatory approval will determine whether that level is eventually reached.

Another step in Eco's vaccine expansion

This agreement appears strategically consistent with Eco Animal Health's move towards prevention and vaccines. It adds a late-stage livestock asset shortly after the EU commercial launch of ECOVAXXIN MS, while management expects to fund development within existing plans.

The key attraction is the combination of a potentially accelerated development pathway and estimated peak annual sales of approximately £10 million in the UK and Europe. The key uncertainty is timing: Eco has not disclosed when the candidate could be approved or begin generating revenue.

Future updates on regulatory progress, development milestones and launch planning will therefore be important. For now, the licence broadens Eco's vaccine opportunity without changing its planned R&D expenditure, but successful commercialisation still has to be delivered.